Altamira Therapeutics Announces Pricing of Up to $12.0 Million Public Offering Page 1

Hamilton, Bermuda, September 17, 2024 (GLOBE NEWSWIRE) —

• $4 million upfront with up to $8 million additional gross proceeds upon full exercise of milestone-linked cash warrants

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets outside the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 shares of its common stock (or pre-funded warrants in lieu thereof), accompanied by Series A-1 common warrants to purchase up to 5,555,556 shares of its common stock and Series A-2 common warrants to purchase up to 5,555,556 shares of its common stock, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrants and Series A-2 common warrants. The Series A-1 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and will expire on the earlier of eighteen months following the original issuance date or 60 days following the date on which the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and will expire on the earlier of five years following the original issuance date or six months following the date on which the Company publicly announces the entering into one or more agreements relating to the further development and commercialization of AM-401 or AM-411, provided that at least one of such agreements covers a territory that includes all or part of the European Union or the United States. The closing of the offering is expected to occur on or about September 19, 2024, subject to the satisfaction of customary closing conditions.

HC Wainwright & Co. is acting as exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from this offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series A-1 common warrants and Series A-2 common warrants, if exercised in full on a cash basis, will be approximately $8.0 million. There can be no assurance that any of the Series A-1 common warrants or Series A-2 common warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.